BMY · NYSE · ·
Next earnings: October 29, 2026 · before the open
$62.88-1.6%Sep 29 close
Bristol Myers Squibb discovers, makes and sells prescription medicines for cancer, blood disorders, immune conditions, heart disease and mental health conditions.
Bristol Myers Squibb Co. is scheduled to report next on October 29, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $13B | $12.3B | +5.74% |
| Profit | $3.3B | $1.3B | +153.21% |
| Profit per share | $1.62 | $0.64 | +153.13% |
| Free Cash Flow | $3.1B | $3.6B | -13.16% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Bristol Myers Squibb Co.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every Bristol Myers Squibb Co. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.